Adaptive Biotechnologies Corporation (ADPT) is a Healthcare stock trading at $25.44 (as of 2026-08-20), with a market capitalization of $4.07B. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ, a platform and core immunosequencing product that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signals; and T-Detect COVID for the confirmation of past COVID-19 infection. It also provides clonoSEQ, a clinical diagnostic product for the detection and monitoring of minimal residual disease in patients with multiple myeloma, B cell acute lymphoblastic leukemia, and chronic lymphocytic leukemia, as well as available as a CLIA-validated laboratory developed test for patients with other lymphoid cancers; and immunoSEQ T-MAP COVID for vaccine developers and researchers to measure the T-cell immune response to vaccines. In addition, the company offers a pipeline of clinical products and services that are used for the diagnosing, monitoring, and treatment of diseases, such as cancer, autoimmune conditions, and infectious diseases. It serves the life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.
Adaptive Biotechnologies develops an immune medicine platform used for disease diagnosis and monitoring, including immunoSEQ (research and diagnostics) and clonoSEQ (minimal residual disease monitoring in multiple myeloma), and it also offers T-Detect COVID for confirming past COVID-19 infection, with money coming from sales of these sequencing and diagnostic products and related services.
The profit model is highly margin-prone on gross basis, but investor outcomes hinge on whether revenue from the companys diagnostic sequencing businesses can eventually cover ongoing operating expenses, since the latest quarter shows a very high gross margin alongside a negative operating margin.
| MRD | $0.1B |
| PharmaSvcs | $0.0B |
| Dev | $0.0B |
Business quality (Weak): Strong gross margin profile, but operating losses indicate the business has not yet scaled to cover operating costs, so performance is likely to be driven by whether diagnostic and research sequencing revenue grows faster than operating spend.
| Price | $25.44 |
| Market Cap | $4.07B |
| Price / Book | 27.02 |
| Price / Sales | 13.22 |
| FCF Yield | -0.9% |
| Revenue (TTM) | $276.98M |
| Net Margin | -21.5% |
| Revenue Growth (YoY) | 21.5% |
| EPS Growth (YoY) | 47.1% |
| FCF Growth (YoY) | -42.0% |
| Altman Z-Score | 5.11 (safe) |
| Piotroski F-Score | 5/9 (moderate) |
| Sector P/E (Healthcare) | 21.6 |
| Industry P/E (Pharmaceutical Products) | 17.2 |
| Top Institutional Holder | VIKING GLOBAL INVESTORS LP ($416.31M) |
| Institutional Holders Tracked | 10 |
| Sector | Healthcare |
| Industry | Pharmaceutical Products |
| CEO | Chad Robins |
| Employees | 619 |
| Country | US |
| IPO Date | 2019-06-27 |
Data as of 2026-08-20.
Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.